Compare · ADCT vs NVO
ADCT vs NVO
Side-by-side comparison of ADC Therapeutics SA (ADCT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADCT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 1464.2x ADCT ($131.0M).
- Over the past year, ADCT is down 73.4% and NVO is down 45.2% - NVO leads by 28.2 points.
- ADCT has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 19 for ADCT).
- Company
- ADC Therapeutics SA
- Novo Nordisk A/S
- Price
- $0.95-7.44%
- $41.34-3.71%
- Market cap
- $131.0M
- $191.82B
- 1M return
- -74.72%
- -9.75%
- 1Y return
- -73.44%
- -45.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 8
- Recent ratings
- 19
- 25
ADC Therapeutics SA
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ADCT
- ADC Therapeutics downgraded by H.C. Wainwright
- ADC Therapeutics downgraded by RBC Capital Mkts with a new price target
- Director Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax
- Director Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation
- Director Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)
- Director Monges Viviane was granted 45,000 shares and covered exercise/tax liability with 2,596 shares, increasing direct ownership by 29% to 186,447 units (SEC Form 4) to cover withholding tax
- Director Hug Peter was granted 45,000 shares and covered exercise/tax liability with 2,156 shares, increasing direct ownership by 19% to 263,344 units (SEC Form 4) to cover withholding tax
- Director Bizzari Jean-Pierre was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 139,302 units (SEC Form 4) to satisfy withholding tax
- Director Coughlin Timothy was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 81% to 72,400 units (SEC Form 4) (tax withholding)
- ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care